NATCO Pharma Limited (NSE:NATCOPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 161.96B |
| Revenue (ttm) | 43.96B |
| Net Income (ttm) | 16.98B |
| Shares Out | 179.11M |
| EPS (ttm) | 94.78 |
| PE Ratio | 9.54 |
| Forward PE | 15.36 |
| Dividend | 6.00 (0.66%) |
| Ex-Dividend Date | Aug 19, 2025 |
| Volume | 593,305 |
| Average Volume | 898,563 |
| Open | 902.00 |
| Previous Close | 904.25 |
| Day's Range | 870.00 - 908.75 |
| 52-Week Range | 726.80 - 1,639.00 |
| Beta | 0.19 |
| RSI | 37.87 |
| Earnings Date | Aug 12, 2025 |
About NATCO Pharma
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosph... [Read more]
Financial Performance
In 2024, NATCO Pharma's revenue was 44.30 billion, an increase of 10.68% compared to the previous year's 40.02 billion. Earnings were 18.85 billion, an increase of 35.81%.
Financial StatementsNews
Natco Pharma board declares interim dividend of Rs 2 per share for FY26
Natco Pharma has declared an interim dividend of ₹2 per equity share (face value ₹2 each), translating to a 100% payout for the financial year 2025-26. The company has set Tuesday, August 19, 2025, as...
NATCO Pharma Q1 Results: Revenue slips marginally to Rs 1,390.6 crore, net profit falls 28.1% YoY
NATCO Pharma has posted its financial results for the first quarter ended June 30, 2025, reporting a consolidated total revenue of ₹1,390.6 crore, down slightly from ₹1,410.7 crore in the same period ...
Natco Pharma gets EIR from USFDA for Hyderabad API facility
NATCO Pharma Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Active Pharmaceutical Ingredient (API) facili...
NATCO Pharma offers to acquire 35.75% stake in South Africa’s Adcock Ingram for Rs 2,000 crore
NATCO Pharma Limited has taken a bold step towards strengthening its international presence by offering to buy out minority shareholders of South Africa-based Adcock Ingram Holdings. The Hyderabad-bas...
Natco Pharma plans to acquire majority stake in South Africa’s Adcock Holdings: Report
According to sources cited by CNBC Awaaz, Natco Pharma is planning to acquire a majority stake in Adcock Holdings, a South Africa-based pharmaceutical company. The Hyderabad-headquartered drug maker i...
Natco Pharma shares dip 2% after company receives one observation from US FDA following Mekaguda API facility inspection
Natco Pharma shares fell 2% in early trade after the company announced that the U.S. Food and Drug Administration (US FDA) concluded a routine inspection at its API (Active Pharmaceutical Ingredients)...
Top stocks to watch today, June 16: NTPC, Godrej Properties, ONGC, Oil India, SpiceJet, Natco Pharma and more
Indian stock markets are likely to open on a cautious note on Monday, June 16, as global investors monitor geopolitical tensions in the Middle East. Here’s a look at key stocks that will be in focus t...
Stocks to watch on June 17: Syngene, Tata Motors, Vedanta, YES Bank, SpiceJet, Sun Pharma, Natco Pharma, Zydus, Ramkrishna Forging
Here’s a look at the key stocks that could be in focus on June 16 based on company announcements, regulatory updates, promoter actions, and sector movements: Syngene: US FDA issues zero observations f...
NATCO Pharma receives one observation after US FDA inspection at Mekaguda API facility
NATCO Pharma Limited has announced the successful conclusion of a routine inspection by the U.S. Food and Drug Administration (US FDA) at its Active Pharmaceutical Ingredients (API) manufacturing faci...
Natco Pharma shares jump 4% as Q4 revenue jumps 14.3% YoY to Rs 1,221 crore
Shares of Natco Pharma jumped 4% in early morning trade following the release of its Q4 results. As of 9:30 AM, the shares were trading 2.64% higher at Rs 885.10. The pharmaceutical major reported a c...
Q4 earnings results today: IRCTC, Deepak Nitrite, Natco Pharma, SAIL, Cummins, Welspun Corp among key companies to report
A host of prominent companies are scheduled to announce their Q4 FY24-25 results today. Market participants will closely monitor the earnings reports for cues on sectoral growth, margin resilience, an...
NATCO Pharma plans to launch generic Risdiplam in India, awaiting court clearance
NATCO Pharma Limited has issued an update regarding the anticipated launch of its generic version of Risdiplam in India. The company has received significant interest from investors and patients conce...
Natco Pharma shares fall 5% today as Trump warns of aggressive pharma tariffs
Shares of Natco Pharma Ltd dropped 5% to ₹794.75 on Friday, falling ₹41.80 from the previous close of ₹836.55, as investor sentiment soured after U.S. President Donald Trump indicated his administrati...
Natco Pharma shares rally over 5% as U.S. exempts Indian generics from tariff blow
Shares of Natco Pharma surged 5.07% to ₹847.45 in Wednesday’s trade, following relief in the pharma sector after U.S. President Donald Trump confirmed that pharmaceutical products would be excluded fr...
Stocks hitting 52-week low today, February 20: Natco Pharma, VIP Industries, Birlasoft and more
The Indian equity markets continued their downward trend for the third consecutive session on February 20, 2024, with both the Sensex and Nifty 50 closing lower. The BSE Sensex dropped 203.22 points (...
Stocks hitting 52-week low today, February 19: Natco Pharma, Godrej Consumer, Trident, BEML and more
The Indian stock market experienced a volatile session on February 19, 2024, with benchmark indices closing marginally lower. The BSE Sensex ended at 75,939.18, down by 28.21 points (-0.04%), while th...
Natco Pharma Ltd (BOM:524816) Q3 2025 Earnings Call Highlights: Navigating Challenges with ...
Natco Pharma Ltd (BOM:524816) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth Plans
Natco Pharma shares drop 30% in 2 days following poor Q3 results
Shares of Natco Pharma have witnessed a sharp 30% decline in just two days following the release of its weak Q3 FY25 earnings. Today, As of 9:37 AM, the shares were trading 8.85% lower at Rs 888.80. T...
Top market losers: Natco Pharma plunges 18.65%, Vijaya Diagnostic down 7.20%, Godfrey Phillips slips 4.18%
The Indian stock market witnessed significant declines in several stocks as selling pressure weighed on select counters. Natco Pharma emerged as the biggest loser, plunging 18.65% to ₹991.45. The stoc...
Natco Pharma shares drop 16% as Q3 revenue falls 37% YoY
Natco Pharma Ltd. witnessed a sharp decline of 16% in its stock price following a disappointing performance in the third quarter of FY25. The pharmaceutical company’s consolidated net profit fell to R...
Natco Pharma Q3 FY25 Results: Revenue down 37.4% to Rs 475 crore, Net Profit declines 37.8% YoY
Natco Pharma Ltd. has reported a significant decline in its financial performance for Q3 FY25, with a sharp drop in revenue, net profit, and EBITDA margins. Key Financial Highlights (Q3 FY25 vs Q3 FY2...
Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets
Lupin Limited (Lupin) and its alliance partner Natco Pharma Limited (Natco) have received approval from the U.S. Food and Drug Administration (FDA) for Natco’s Abbreviated New Drug Application (ANDA) ...
NATCO Pharma secures final FDA approval for Generic Bosentan TFOS 32mg
NATCO Pharma Limited has received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer®...
Natco Pharma secures USFDA approval for generic Everolimus tablets, eyes $112 million market
Natco Pharma Limited has announced that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) in 2mg, 3mg, and 5mg strengths....
Healthcare Stocks: Yatharth Hospital down 8.73%, Suven Pharma up 2%, AstraZeneca up 1.22%
Healthcare stocks witnessed mixed performance in the trading session, reflecting varied investor sentiment across the sector. Below is a detailed analysis of major gainers and losers: Top Gainers Suve...